SLC25A51P1: A Potential Drug Target and Biomarker (G442229)

Target Name: SLC25A51P1

NCBI ID: G442229

SLC25A51P1

Other Name(s): bA707M13.1 | MCART3P | BA707M13.1 | SLC25A51 pseudogene 1

SLC25A51P1: A Potential Drug Target and Biomarker

SLC25A51P1 (bA707M13.1) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is a member of the SLC25 family of transport proteins, which are involved in the transport of a variety of molecules across cell membranes. SLC25A51P1 is characterized by its ability to transport the amino acid leucine, which is important for the structure and function of proteins.

SLC25A51P1 has been identified as a potential drug target due to its involvement in the transport of leucine across cell membranes. Leucine is an essential amino acid that is involved in the formation and repair of proteins, and it is also a key precursor to the neurotransmitter serotonin . Imbalances in leucine levels have been linked to a number of neurological and psychiatric disorders, including depression, anxiety, and schizophrenia.

SLC25A51P1 has also been shown to play a role in the regulation of ion channels in cells. In particular, it has been shown to be involved in the regulation of the channelprotein K channels, which are involved in the rapid transport of ions through cell membranes . Imbalances in potassium levels have been linked to a number of physiological processes, including muscle and nerve function, as well as the regulation of heart rhythm.

In addition to its role in the regulation of ion channels, SLC25A51P1 has also been shown to play a role in the regulation of protein synthesis and degradation. It is involved in the transport of amino acids across cell membranes, which is necessary for the synthesis of new proteins. It is also involved in the degradation of damaged proteins, which is important for maintaining cellular homeostasis.

SLC25A51P1 is also a good candidate for a biomarker for certain diseases. For example, it has been shown to be elevated in the brains of individuals with Alzheimer's disease, which is a degenerative brain disorder characterized by the progressive loss of brain cells. Additionally, SLC25A51P1 has also been shown to be elevated in the blood of individuals with Parkinson's disease, which is a motor neuron disorder characterized by the progressive loss of motor neurons.

In conclusion, SLC25A51P1 (bA707M13.1) is a protein that is expressed in various tissues of the body and is involved in the transport of leucine across cell membranes. It has been identified as a potential drug target due to its involvement in the regulation of ion channels and protein synthesis and degradation. Furthermore, SLC25A51P1 has also been shown to play a role in the regulation of protein synthesis and degradation and has been identified as a potential biomarker for a number of diseases. Further research is needed to fully understand the role of SLC25A51P1 in the regulation of ion channels and protein synthesis and degradation, as well as its potential as a drug target and biomarker.

Protein Name: SLC25A51 Pseudogene 1

The "SLC25A51P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A51P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets